L
Título: Excision of the primary tumour in patients with metastatic breast cancer: a clinical dilemma
Autores: Samiee, S.; University of Ottawa and the Ottawa Hospital Cancer Centre
Berardi, P.; University of Ottawa and Ottawa General Hospital
Bouganim, N.; University of Ottawa and the Ottawa Hospital Cancer Centre
Vandermeer, L.; University of Ottawa and the Ottawa Hospital Cancer Centre
Arnaout, A.; University of Ottawa and Ottawa General Hospital
Dent, S.; University of Ottawa and the Ottawa Hospital Cancer Centre
Mirsky, D.; Queensway Carleton Hospital, Ottawa
Chasen, M.; University of Ottawa and the Ottawa Hospital Cancer Centre
Caudrelier, J.M.; University of Ottawa and the Ottawa Hospital Cancer Centre
Clemons, M.; University of Ottawa and the Ottawa Hospital Cancer Centre
Fecha: 2012-08-02
Publicador: Multimed Inc.
Fuente: Ver documento
Tipo: info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion

Tema: Metastatic breast cancer; surgery; local excision
Descripción: Background Approximately 10% of new breast cancer patients will present with overt synchronous metastatic disease. The optimal local management of those patients is controversial. Several series suggest that removal of the primary tumour is associated with a survival benefit, but the retrospective nature of those studies raises considerable methodologic challenges. We evaluated our clinical experience with the management of such patients and, more specifically, the impact of surgery in patients with synchronous metastasis. Methods We reviewed patients with primary breast cancer and concurrent distant metastases seen at our centre between 2005 and 2007. Demographic and treatment data were collected. Study endpoints included overall survival and symptomatic local progression rates. Results The 111 patients identified had a median follow-up of 40 months (range: 0.6–71 months). We allocated the patients to one of two groups: a nonsurgical group (those who did not have breast surgery, n = 63) and a surgical group (those who did have surgery, n = 48, 29 of whom had surgery before the metastatic diagnosis). When compared with patients in the nonsurgical group, patients in the surgical group were less likely to present with T4 tumours (23% vs. 35%), N3 nodal disease (8% vs. 19%), and visceral metastasis (67% vs. 73%). Patients in the surgical group experienced longer overall survival (49 months vs. 33 months, p = 0.01) and lower rates of symptomatic local progression (14% vs. 44%, p < 0.001). Conclusions In our study, improved overall survival and symptomatic local control were demonstrated in the surgically treated patients; however, this group had less aggressive disease at presentation. The optimal local management of patients with metastatic breast cancer remains unknown. An ongoing phase III trial, E2108, has been designed to assess the effect of breast surgery in metastatic patients responding to first-line systemic therapy. If excision of the primary tumour is associated with a survival benefit, then the preselected subgroup of patients who have responded to initial systemic therapy is the desired population in which to put this hypothesis to the test.   
Idioma: Inglés
Artículos similares:
Massage Therapy for Cancer Patients: A Reciprocal Relationship Between Body and Mind por Sagar, Stephen,Dryden, Trish; Centre for Applied Research, Centennial College,Wong, Raimond K; McMaster University, Departments of Medicine and Oncology
Cord stem-cell transplantation in Ontario: do we need a public bank? por Gassas, A.; the Hospital for Sick Children, Toronto
Integrating Science and Human Values for Cancer Patient Care por Sutcliffe, Simon B.; BC Cancer Agency
Assessment and management of febrile neutropenia in emergency departments within a regional health authority—a benchmark analysis por Szwajcer, D.; University of Manitoba,Czaykowski, P.; University of Manitoba,Turner, D.; CancerCare Manitoba
Conservative Treatment of Invasive Bladder Cancer por Souhami, Luis; McGill University,Rene, Nicholas,Cury, Fabio Biagini
Liver transplantation for symptomatic liver metastases of neuroendocrine tumours por Chan, G.; Hôpital Maisonneuve-Rosemont Université de Montréal,Kocha, W.,Reid, R.,Taqi, A.,Wall, W.,Quan, D.
10 
What is the optimal management of dysphagia in metastatic esophageal cancer? por Cavallin, F.; Veneto Institute of Oncology,Scarpa, M.; Veneto Institute of Oncology,Cagol, M.; Veneto Institute of Oncology,Alfieri, R.; Veneto Institute of Oncology,Castoro, C.; Veneto Institute of Oncology